---
title: First quarter 2020 financial report
description: Gentian Diagnostics AS announces its results for the first quarter of 2020.
---

Moss, 24 April 2020

Gentian Diagnostics AS announces its results for the first quarter of 2020.

The highlights include:

- Record sales revenues of MNOK 16.2 in 1Q20, up from MNOK 10.6 in 1Q19
- Sales growth of 53 % is based on strong performance of all product lines. Sales grew by 42 % YoY on a currency neutral basis
- New publications of clinical study results confirm GCAL as a promising biomarker for earlier detection and better prediction of severity of an infection

Please find the report and results presentation here:

[GDAS 1Q 2020 Interim report](https://www.gentian.com/hubfs/GDAS%201Q%202020%20Interim%20report.pdf)

[GDAS 1Q Interim Presentation](https://www.gentian.com/hubfs/GDAS%201Q%20Interim%20presentation.pdf)

 

**For further information, please contact: **

Hilja Ibert CEO, Gentian Diagnostics   
E-mail: [hilja.ibert@gentian.no ](mailto:hilja.ibert@gentian.no)  
Cell Phone: +47 919 05 242

Njaal Kind CFO, Gentian Diagnostics   
E-mail: [njaal.kind@gentian.no ](mailto:njaal.kind@gentian.no)  
Cell Phone. +47 919 06 525

**MeldingsID:** 503693  
**UtstederID:** GENT-ME  
**Marked:** Merkur Market

### You may also read

[Jul 02, 2026 - Ole Sørlie](https://www.gentian.com/investor-relations-stock-information/investors-news/first-quarter-2020-financial-report#)

##### [Gentian Diagnostics: Invitation to presentation of second quarter results](https://www.gentian.com/investor-relations-stock-information/investors-news/gentian-diagnostics-invitation-to-presentation-of-second-quarter-results-1)

Gentian Diagnostics ASA will present its second quarter 2026 results on 9 July 2026 at 09.00 CEST. The..

[Read more](https://www.gentian.com/investor-relations-stock-information/investors-news/gentian-diagnostics-invitation-to-presentation-of-second-quarter-results-1)

[Jun 24, 2026 - Ole Sørlie](https://www.gentian.com/investor-relations-stock-information/investors-news/first-quarter-2020-financial-report#)

##### [ESSANGE REAGENTS AND GENTIAN DIAGNOSTICS ANNOUNCE COLLABORATION AGREEMENT](https://www.gentian.com/investor-relations-stock-information/investors-news/essange-reagents-and-gentian-diagnostics-announce-collaboration-agreement)

Amsterdam / Moss, 24 June 2026 ESSANGE REAGENTS AND GENTIAN DIAGNOSTICS ANNOUNCE COLLABORATION AGREEMENT..

[Read more](https://www.gentian.com/investor-relations-stock-information/investors-news/essange-reagents-and-gentian-diagnostics-announce-collaboration-agreement)

[May 29, 2026 - Ole Sørlie](https://www.gentian.com/investor-relations-stock-information/investors-news/first-quarter-2020-financial-report#)

##### [Mandatory notification of trade](https://www.gentian.com/investor-relations-stock-information/investors-news/mandatory-notification-of-trade-1780055230560)

Moss, 29 May 2026 Gentian Diagnostics ASA ("Gentian") has today been notified that the following transaction..

[Read more](https://www.gentian.com/investor-relations-stock-information/investors-news/mandatory-notification-of-trade-1780055230560)